Less Ads, More Data, More Tools Register for FREE

Pin to quick picksClarkson Regulatory News (CKN)

Share Price Information for Clarkson (CKN)

Share Price is delayed by 15 minutes
Get Live Data
4,608.00    24.00 (0.52%)
Bid:
4,604.00
Ask:
4,612.00
Spread: 8.00 (0.174%)
Market Cap: £1.42b
CKN Live PriceLast checked at - London Stock Exchange

Intraday Clarkson Share Chart

UPDATE RE ACQUISITION

28 Jan 2015 07:00

RNS Number : 3127D
Clarkson PLC
28 January 2015
 



This announcement and the information contained herein is restricted and is not for release, publication or distribution, directly or indirectly, in whole or in part, in, into or from australia, canada, Japan, the republic of south africa, the united states or any other jurisdiction in which the same would be unlawful. please see the important notice at the end of this announcement.

 

CLARKSON PLC

 

Update re acquisition

 

28 January 2015

 

Further to the announcement by Clarkson PLC ("Clarksons") on 27 November 2014 of its proposed acquisition of RS Platou ASA and the further announcement on 23 December 2014 regarding the result of the General Meeting and shareholder approval of the Acquisition, Clarksons is today pleased to announce that it has now obtained certain regulatory approvals that were conditions to Completion of the Acquisition.

 

As a result, in accordance with paragraph 5.6.19G of the Listing Rules, applications have been made to the Financial Conduct Authority for re-admission of the Existing Ordinary Shares and the admission of the Consideration Shares to the premium listing segment of the Official List and to trading on the London Stock Exchange's main market for listed securities. It is expected that, subject to the fulfilment of the remaining conditions, Completion of the Acquisition and Re-Admission will occur at 8.00 a.m. on 2 February 2015.

 

Under the terms of the Acquisition, the final number of Consideration Shares to be allotted and issued by Clarksons to the Sellers is 9,518,369 and following Re-Admission it is anticipated that the total number of ordinary shares that the Company has in issue will be 30,116,758.

 

Capitalised terms used in this announcement shall have the meanings as set out in the prospectus published by Clarksons on 17 December 2014.

 

For further information contact:

 

Clarkson PLC

+44 207 334 0000

Andi Case

Jeff Woyda

Nomura International plc

+44 207 102 1000

Andrew McNaught

Andrew Forrester

Nicholas Marren

Panmure Gordon (UK) Limited

Richard Gray

Andrew Potts

Tom Salvesen

+44 207 886 2500

Hudson Sandler

+44 207 796 4133

Andrew Nicolls

 

IMPORTANT NOTICE

This Announcement and the information contained in it is restricted and is not for release, publication or distribution, directly or indirectly, in whole or in part, in, into or from the United States (including its territories and possessions, any state of the United States and the District of Columbia, collectively the "United States") Australia, Canada, Japan or the Republic of South Africa or any other state or jurisdiction in which the same would be restricted, unlawful or unauthorised (each a "Restricted Territory"). This Announcement is for information purposes only and does not constitute an offer to sell or issue or the solicitation of an offer to buy, acquire or subscribe for shares in the capital of the Company in any Restricted Territory or to any person to whom it is unlawful to make such offer or solicitation. Any failure to comply with these restrictions may constitute a violation of the securities laws of such jurisdictions. Subject to certain exemptions, the securities referred to herein may not be offered or sold in any Restricted Territory or for the account or benefit of any national resident or citizen of any Restricted Territory.

This Announcement and the information contained herein is not an offer of securities for sale in the United States and there will be no public offer of securities in the United States. The securities discussed herein have not been and will not be registered under the United States Securities Act of 1933, as amended (the "Securities Act") or the securities laws or with any securities regulatory authority of any other state or other jurisdiction of the United States, and may not be offered, sold or transferred, directly or indirectly, in the United States absent registration under the Securities Act or an available exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with any applicable securities laws of any other state or jurisdiction of the United States.

This Announcement has been issued by, and is the sole responsibility of the Company. No representation or warranty express or implied, is or will be made as to, or in relation to, and no responsibility or liability is or will be accepted by Nomura International plc ("Nomura") or Panmure Gordon (UK) Limited ("Panmure Gordon") or by any of their respective affiliates or agents as to or in relation to, the accuracy or completeness of this Announcement or any other written or oral information made available to or publicly available to any interested party or its advisers, and any liability therefore is expressly disclaimed.

Nomura, which is authorised by the Prudential Regulation Authority and is regulated by the Financial Conduct Authority in the United Kingdom, is acting solely for the Company in relation to the Acquisition and nobody else and will not be responsible to anyone other than the Company for providing the protections afforded to its clients nor for providing advice in relation to the Acquisition or any other matter referred to in this Announcement. Apart from the responsibilities and liabilities, if any, which may be imposed on Nomura by the Financial Services and Markets Act 2000 or by the regulatory regime established under it, neither Nomura nor any of its respective affiliates accepts any responsibility whatsoever for the contents of the information contained in this Announcement or for any other statement made or purported to be made by or on behalf of Nomura or any of its respective affiliates in connection with the Company or the Acquisition. Nomura and its respective affiliates accordingly disclaim all and any liability, whether arising in tort, contract or otherwise (save as referred to above) in respect of any statements or other information contained in this Announcement and no representation or warranty, express or implied, is made by Nomura or any of its respective affiliates as to the accuracy, fairness, verification, completeness or sufficiency of the information contained in this Announcement. Nothing in this Announcement is, or shall be relied upon as, a promise or representation in this respect, whether as to the past or the future.

Panmure Gordon, which is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority in the United Kingdom, is acting solely for the Company and nobody else and will not be responsible to anyone other than the Company for providing the protections afforded to its clients nor for providing advice in relation to any matter referred to in this Announcement. Apart from the responsibilities and liabilities, if any, which may be imposed on Panmure Gordon by the Financial Services and Markets Act 2000 or by the regulatory regime established under it, neither Panmure Gordon nor any of its respective affiliates accepts any responsibility whatsoever for the contents of the information contained in this Announcement or for any other statement made or purported to be made by or on behalf of Panmure Gordon or any of its respective affiliates in connection with the Company. Panmure Gordon and its respective affiliates accordingly disclaim all and any liability, whether arising in tort, contract or otherwise (save as referred to above) in respect of any statements or other information contained in this Announcement and no representation or warranty, express or implied, is made by Panmure Gordon or any of its respective affiliates as to the accuracy, fairness, verification, completeness or sufficiency of the information contained in this Announcement. Nothing in this Announcement is, or shall be relied upon as a promise or representation in this respect, whether as to the past or the future.

This Announcement does not constitute or form part of, and should not be construed as, an offer, solicitation or invitation to subscribe, for, underwrite or otherwise acquire, any securities of the Company or any member of its group in any jurisdiction or an inducement to enter into investment activity.

The information in this Announcement may not be forwarded or distributed to any other person and may not be reproduced in any manner whatsoever. Any forwarding, distribution, reproduction, or disclosure of this information in whole or in part is unauthorised. Failure to comply with this directive may result in a violation of the Securities Act or the applicable laws of other jurisdictions.

The information contained in this Announcement is subject to change without notice and, except as required by applicable law, the Company does not assume any responsibility or obligation to update publicly or review any of the forward-looking statements contained herein. You should not place undue reliance on forward-looking statements, which speak only as of the date of this Announcement.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
ACQSEAFAWFISEDF
Date   Source Headline
1st Jun 202612:00 pmRNSTotal Voting Rights
15th May 20267:00 amRNSDirector/PDMR Shareholding
14th May 20264:30 pmRNSDirector/PDMR Shareholding
7th May 20264:45 pmRNSResult of AGM
7th May 202612:00 pmRNSTrading Statement
1st May 202612:00 pmRNSTotal Voting Rights
27th Apr 20263:00 pmRNSBlock Listing Interim Review
27th Apr 202612:00 pmRNSHolding(s) in Company
23rd Apr 20265:00 pmRNSHolding(s) in Company
21st Apr 20265:00 pmRNSDirector/PDMR Shareholding
1st Apr 20263:30 pmRNSTotal Voting Rights
30th Mar 20265:55 pmRNSAnnual Report and Notice of AGM
19th Mar 20263:00 pmRNSDirector/PDMR Shareholding
18th Mar 20261:21 pmRNSAcquisition of the Link Group
9th Mar 20267:00 amRNSPreliminary results
4th Mar 20263:30 pmRNSHolding(s) in Company
2nd Feb 202612:00 pmRNSTotal Voting Rights
9th Jan 20267:00 amRNSTrading Statement
8th Jan 202612:41 pmRNSAcquisition of Zuma Labs Limited
2nd Jan 202612:00 pmRNSTotal Voting Rights
1st Dec 202512:00 pmRNSTotal Voting Rights
3rd Nov 202512:00 pmRNSTotal Voting Rights
27th Oct 202512:00 pmRNSBlock listing Interim Review
24th Oct 20259:00 amRNSAdditional Listing
21st Oct 20253:30 pmRNSDirector/PDMR Shareholding
2nd Oct 202512:00 pmRNSCompany Secretary Change
16th Sep 20257:00 amRNSRetirement of Director
1st Sep 202511:00 amRNSTotal Voting Rights
4th Aug 20257:00 amRNSInterim results
1st Jul 202512:00 pmRNSTotal Voting Rights
2nd Jun 202511:00 amRNSTotal Voting Rights
21st May 20254:30 pmRNSDirector/PDMR Shareholding
2nd May 202511:30 amRNSDirector/PDMR Shareholding
1st May 20256:00 pmRNSResult of AGM
1st May 20253:00 pmRNSDirector/PDMR Shareholding
1st May 202512:27 pmRNSTotal Voting Rights
1st May 20257:00 amRNSTrading Statement
28th Apr 20256:00 pmRNSBlock listing Interim Review
23rd Apr 20255:30 pmRNSDirector/PDMR Shareholding
22nd Apr 20253:00 pmRNSHolding(s) in Company
15th Apr 20255:00 pmRNSDirector/PDMR Shareholding
1st Apr 20252:30 pmRNSTotal Voting Rights
25th Mar 20255:15 pmRNSAnnual Financial Report
13th Mar 20253:00 pmRNSHolding(s) in Company
12th Mar 20252:00 pmRNSDirector/PDMR Shareholding
10th Mar 20257:00 amRNSPreliminary results
3rd Feb 202512:30 pmRNSTotal Voting Rights
31st Jan 20255:00 pmRNSHolding(s) in Company
13th Jan 20254:30 pmRNSHolding(s) in Company
10th Jan 20257:00 amRNSTrading Statement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.